In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...
The Motley Fool on MSN1d
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.The company is well-positioned to continue gaining momentum against Novo in weight loss while simultaneously leading the ...
8don MSN
We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
Insider Monkey on MSN14d
Why Is Eli Lilly and Company (LLY) Among the Best Income Stocks to Buy According to Analysts?We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback